Patents by Inventor Amelia Nancy Black

Amelia Nancy Black has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibodies against CD30 lacking in fucosyl residues
    Patent number: 8491898
    Abstract: The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: July 23, 2013
    Assignee: Medarex, L.L.C.
    Inventors: Josephine M. Cardarelli, Amelia Nancy Black
  • MONOCLONAL ANTIBODIES AGAINST CD30 LACKING IN FUCOSYL AND XYLOSYL RESIDUES
    Publication number: 20120276086
    Abstract: The invention pertains to anti-CD30 antibodies that lack fucosyl and xylosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated and xylosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl and xylosyl residues, wherein the host cells are deficient for a fucosyltransferase and a xylosyltransferase. Methods of using the antibodies to inhibit the grown of CD30+ cells, such as tumor cells, are also provided.
    Type: Application
    Filed: April 18, 2012
    Publication date: November 1, 2012
    Applicants: MEDAREX, INC., BIOLEX THERAPEUTICS, INC.
    Inventors: Amelia Nancy BLACK, David B. PASSMORE, Mohan SRINIVASAN, Lynn F. DICKEY, Kevin M. COX, Charles G. PEELE, Ming-Bo WANG
  • MONOCLONAL ANTIBODIES AGAINST CD30 LACKING IN FUCOSYL RESIDUES
    Publication number: 20120251533
    Abstract: The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.
    Type: Application
    Filed: May 2, 2012
    Publication date: October 4, 2012
    Applicant: MEDAREX, INC.
    Inventors: Josephine M. CARDARELLI, Amelia Nancy BLACK
  • Monoclonal antibodies against CD30 lacking in fucosyl residues
    Patent number: 8207303
    Abstract: The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: June 26, 2012
    Assignee: Medarex, Inc.
    Inventors: Josephine M. Cardarelli, Amelia Nancy Black
  • Monoclonal Antibodies Against CD30 Lacking in Fucosyl Residues
    Publication number: 20100021479
    Abstract: The invention pertains to anti-CD30 antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated form of the antibodies. The invention also provides host cells that express the anti-CD30 antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of CD30+ cells, such as tumor cells, are also provided.
    Type: Application
    Filed: February 17, 2006
    Publication date: January 28, 2010
    Applicant: MEDAREX INC.
    Inventors: Josephine M. Cardarelli, Amelia Nancy Black